Document is current

Article History

Received: 21 June 2024

Accepted: 14 August 2024

First Online: 9 September 2024

Declarations

:

: Mohamed Hassanein is an advisory board member for Sanofi, Boehringer Ingelheim and Novo Nordisk and a speaker for Eli Lilly and Company, Janssen, LifeScan, Merck Sharp and Dohme, Novo Nordisk and Sanofi and has received lecturer/other fees from Sanofi, Novo Nordisk, Eli Lilly and Company, Merck Sharp and Dohme, Janssen and LifeScan. Rachid Malek has received speaker fees and advisory board honoraria from Novo Nordisk. Saud Al Sifri has acted as an adviser and speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, MSD, Novartis, Novo Nordisk and Sanofi. Rakesh Kumar Sahay is an advisory board member for Boehringer Ingelheim, Dr. Reddy’s Laboratories, Eli Lilly and Company and Sanofi and a speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. Mehmet Akif Buyukbese has received speaker fees from Eli Lilly and Company and speaker/other fees from Novartis and Sanofi. Khier Djaballah is an employee of Sanofi and may hold shares/stocks in the company. Lydie Melas-Melt is an employee of IVIDATA Life Sciences. Inass Shaltout is a speaker and advisory board member for Sanofi, Novartis, MSD, AstraZeneca, Novo Nordisk, Eli Lilly and Company, Servier and Abbott.

: All participants provided written informed consent. This study was conducted in accordance with the Declaration of Helsinki of 1964 and all subsequent amendments. The study protocol was approved by the local institutional review board/independent ethics committee of the country of each participating investigator (Supplementary Table ), and regulatory submissions were performed in accordance with the local data protection guidelines.